 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12345678910111213...3738» |
- ||| Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
P3 data, Journal, Metastases: Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. (Pubmed Central) - Oct 30, 2023
P3
Sacituzumab govitecan demonstrated statistically significant and clinically meaningful benefit over chemotherapy, with a 3
- Halaven (eribulin mesylate) / Eisai
(Companion Study): Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician (Regency A (Ballroom Level, West Tower)) - Oct 28, 2023 - Abstract #SWOGFall2023SWOG_Fall_130;
Sacituzumab govitecan demonstrated statistically significant and clinically meaningful benefit over chemotherapy, with a 3 Participants will be described by physician
- Halaven (eribulin mesylate) / Eisai
A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician (Regency A (Ballroom Level, West Tower)) - Oct 28, 2023 - Abstract #SWOGFall2023SWOG_Fall_104;
Participants will be described by physician Participants will be described by physician
- | everolimus / Generic mfg.
Enrollment open, Metastases: BCTOP-T-M03: Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype (clinicaltrials.gov) - Oct 26, 2023
P3, N=203, Recruiting, Sponsor: Fudan University
Participants will be described by physician Not yet recruiting --> Recruiting
- | New P2 trial, Metastases: ORIENTA: Organoid-based Functional Precision Therapy for Advanced Breast Cancer (clinicaltrials.gov) - Oct 25, 2023
P2, N=252, Not yet recruiting, Sponsor: Guangdong Provincial People's Hospital
- | Halaven (eribulin mesylate) / Eisai
Journal, Metastases: Interleukin-6 and C-Reactive protein in metastatic breast cancer patients treated with eribulin. (Pubmed Central) - Oct 25, 2023
Not yet recruiting --> Recruiting No abstract available
- ||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Korlym (mifepristone) / Corcept Therap, Mifeprex (mifepristone) / Danco Laboratories
New P2 trial, Combination therapy, Metastases: TBCRC 058: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer (clinicaltrials.gov) - Oct 25, 2023
P2, N=201, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- ||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment closed, Metastases: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) - Oct 23, 2023
P3, N=254, Active, not recruiting, Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
No abstract available Not yet recruiting --> Active, not recruiting
- |||||| Bria-IMT (SV-BR-1-GM) / BriaCell
Enrollment open, Metastases: BRIA-ABC: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (clinicaltrials.gov) - Oct 23, 2023
P3, N=404, Recruiting, Sponsor: BriaCell Therapeutics Corporation
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Halaven (eribulin mesylate) / Eisai
Review, Journal, Metastases: Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review. (Pubmed Central) - Oct 16, 2023
In the advanced setting, specific systemic therapy such as eribulin and trabectedin showed promising activity in comparison to conventional therapy (doxorubicin- and gemcitabine-based protocols), which currently remains the current standard of care at initial stages of the disease. The better understanding of soft tissue sarcoma (STS) pathophysiology and disease course has led to the development of adapted clinical trial designs for rare STS histotypes with specific treatment approach.
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Monotherapy, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Oct 16, 2023
P3, N=302, Active, not recruiting, Sponsor: AstraZeneca
The better understanding of soft tissue sarcoma (STS) pathophysiology and disease course has led to the development of adapted clinical trial designs for rare STS histotypes with specific treatment approach. Trial completion date: Sep 2023 --> Dec 2023
- || Halaven (eribulin mesylate) / Eisai
Clinical, Retrospective data, Journal, Metastases: Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study. (Pubmed Central) - Oct 16, 2023
Hematologic toxicity (leukopenia and neutropenia) was the most common grade ?3 AEs, and AEs were more common in patients in greater than or equal to third line. The results suggest that eribulin combined with antiangiogenic therapy has a meaningful clinical activity and an acceptable safety profile in HER2-negative MBC.
- | Halaven (eribulin mesylate) / Eisai
Preclinical, Journal: Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer. (Pubmed Central) - Oct 14, 2023
Mechanistically, we demonstrated that the effect of the combination could be enhanced by inhibiting both the PI3K/AKT and EMT pathways. Therefore, we suggest that paclitaxel resistance is associated with the activation of the PIK3/AKT pathway in PIK3CA-mutated endometrial cancer, and the combination of a PI3K inhibitor and eribulin merits further clinical investigation.
- | sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P3 trial, Metastases: A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov) - Oct 13, 2023
P3, N=376, Not yet recruiting, Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
- |||||||||| JSKN003 / Alphamab
New P3 trial, Metastases: JSKN003-302: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects (clinicaltrials.gov) - Oct 12, 2023
P3, N=400, Not yet recruiting, Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- | Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: PATRICIA: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 10, 2023
P2, N=102, Active, not recruiting, Sponsor: SOLTI Breast Cancer Research Group
Therefore, we suggest that paclitaxel resistance is associated with the activation of the PIK3/AKT pathway in PIK3CA-mutated endometrial cancer, and the combination of a PI3K inhibitor and eribulin merits further clinical investigation. Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Dec 2023
- |||||||||| Bria-IMT (SV-BR-1-GM) / BriaCell
New P3 trial, Metastases: BRIA-ABC: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (clinicaltrials.gov) - Oct 9, 2023
P3, N=404, Not yet recruiting, Sponsor: BriaCell Therapeutics Corporation
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_652;
T-emtansine, capecitabine + TP, T-deruxtecan, and epirubicin + cyclophosphamide were administered after ETP with CBR of 72.2% (13/18 patients), 80.0% (4/5 patients), 66.7% (2/3 patients) and 33.3% (1/3 patients), respectively. Conclusions ETP therapy showed acceptable efficacy and overall survival as first-line therapy for patients with HER2-positive Japanese MBC.
- Halaven (eribulin mesylate) / Eisai
Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_645;
Conclusions In this cohort of pts with heavily pre-treated HER2- mBC, ErCb demonstrated promising efficacy and a manageable safety profile. Further studies exploring this combination in earlier lines of treatment for mBC are warranted.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date, Metastases: A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Oct 6, 2023
P2, N=90, Completed, Sponsor: Dana-Farber Cancer Institute
Further studies exploring this combination in earlier lines of treatment for mBC are warranted. Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Sep 2023
- Halaven (eribulin mesylate) / Eisai
B Combination Treatment With Eribulin And Ttfields Induces Apoptosis And G2/M Cell Cycle Arrest In Human Glioblastoma Cells (Grote Zaal Foyer) - Sep 28, 2023 - Abstract #EANO2023EANO_306;
Furthermore the combination therapy effects the cell cycle of glioblastoma cells inducing G2/M arrest. Future preclinical studies should focus on the antimitotic effect and the influence of the treatment on genome integrity for a more detailed insight into the mechanisms of action.
- datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2 (Madrid Auditorium - Hall 6) - Sep 27, 2023 - Abstract #ESMO2023ESMO_4208;
P1, P3
Methods Adult pts with inoperable or metastatic HR+/HER2-BC, who had experienced progression on endocrine therapy (ET) and for whom ET was unsuitable, and who had received 1-2 prior lines of systemic chemotherapy (CT), were randomised 1:1 to Dato-DXd (6 mg/kg Q3W) or investigator's choice of CT (ICC; eribulin, vinorelbine, capecitabine, or gemcitabine) until progression or unacceptable toxicity. Results support Dato-DXd as a novel treatment option for pts with inoperable or metastatic HR+/HER2-BC who have received 1
- Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Characterizing macrophage heterogeneity in HR+/HER2- metastatic breast cancer reveals novel mechanisms of resistance (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1219;
The analysis also suggests that the presence of specific macrophage subsets is associated with worse clinical outcomes (figure 1). Deep phenotyping of the myeloid compartment on serial sections by CyCIF is ongoing.
- Halaven (eribulin mesylate) / Eisai, Opdivo (nivolumab) / Ono Pharma, BMS
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2 negative metastatic breast cancer (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1126;
P1/2
Conclusions In conclusion, we found that high TMB and B-cell related enrichment were associated with good efficacy while HRD was associated with poor efficacy of eribulin plus nivolumab in patients with HER-2 negative metastatic breast cancer. The implications from our study would need to be considered when designing the clinical trial in terms of biomarker enrichment and inclusion/exclusion criteria.
- | Halaven (eribulin mesylate) / Eisai
Biomarker, Journal, Metastases: Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin. (Pubmed Central) - Sep 21, 2023
Our results show that high IL-6 is associated with higher levels of MDSCs which suppress anti-tumor immunity, such as CD8?cells. It appears that eribulin is not particularly effective in patients with high IL-6 due to a poor tumor immune microenvironment.
- | Halaven (eribulin mesylate) / Eisai, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Preclinical, Journal, Combination therapy, IO biomarker: Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma. (Pubmed Central) - Sep 16, 2023
To our knowledge, this is the first preclinical study demonstrating the anti-cancer therapeutic potential of using a combination of selinexor and eribulin in vivo. Results from this study further warrant clinical testing a combination of chemotherapy agents with selinexor to reduce the morbidity and mortality from ULMS.
- Halaven (eribulin mesylate) / Eisai, farletuzumab ecteribulin (MORAb-202) / Eisai, BMS
Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cancer. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_503;
- Halaven (eribulin mesylate) / Eisai
EZH2 inhibition re-sensitizes drug resistant triple-negative breast cancer PDX models to Eribulin. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_205;
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Surgery: Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - Sep 14, 2023
P1b, N=15, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Results from this study further warrant clinical testing a combination of chemotherapy agents with selinexor to reduce the morbidity and mortality from ULMS. Trial completion date: Aug 2024 --> Apr 2033 | Trial primary completion date: Aug 2023 --> Feb 2023
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: ERASING: Eribulin in Advanced Solitary Fibrous Tumor (clinicaltrials.gov) - Sep 13, 2023
P2, N=16, Recruiting, Sponsor: Italian Sarcoma Group
Trial completion date: Aug 2024 --> Apr 2033 | Trial primary completion date: Aug 2023 --> Feb 2023 Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- |||| Enrollment open, Metastases: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Sep 11, 2023
P1/2, N=242, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024 Active, not recruiting --> Recruiting
- |||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial primary completion date, Metastases: EVER-132-002: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Sep 6, 2023
P3, N=331, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Recruiting Trial primary completion date: Mar 2024 --> Apr 2023
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Metastases: EMBRACE: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (clinicaltrials.gov) - Sep 6, 2023
P3, N=201, Suspended, Sponsor: Academic and Community Cancer Research United
Trial primary completion date: Mar 2024 --> Apr 2023 Trial completion date: Sep 2022 --> Dec 2023
- || Halaven (eribulin mesylate) / Eisai
P2 data, Clinical Trial,Phase II, Journal, Metastases: Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03). (Pubmed Central) - Aug 29, 2023
However, less frequent visits are convenient, and reduced dose intensity improves safety. Biweekly administration, besides dose reduction, could be an acceptable option for patients who are unable to maintain a standard regimen.
- | Halaven (eribulin mesylate) / Eisai
New P1/2 trial, Combination therapy: A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Aug 23, 2023
P1/2, N=48, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Halaven (eribulin mesylate) / Eisai
Trial completion date: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (clinicaltrials.gov) - Aug 15, 2023
P2, N=22, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Biweekly administration, besides dose reduction, could be an acceptable option for patients who are unable to maintain a standard regimen. Trial completion date: Dec 2023 --> Dec 2026
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Halaven (eribulin mesylate) / Eisai
Clinical, Journal, Metastases: Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study. (Pubmed Central) - Aug 9, 2023
The rates of any grade and grade ?3 eribulin-induced PN observed in this real-world study were consistent with those observed in phase III randomized clinical trials. No new safety findings were observed.
- Halaven (eribulin mesylate) / Eisai, BB-1701 / BlissBio, Eisai
Development of BB-1701 () - Aug 9, 2023 - Abstract #ADCUSA2023ADC_USA_125;
No new safety findings were observed. Introducing BB-1701, an anti-HER2 ADC with Eribulin payload; Evaluating preclinical bioactivity and toxicity/pharmacokinetics; Discussing Phase 1 clinical data of BB-1701; Exploring the future of Bliss Bio's BB-1701
- || Phase classification, Enrollment change: SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) - Aug 8, 2023
P1, N=25, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
Introducing BB-1701, an anti-HER2 ADC with Eribulin payload; Evaluating preclinical bioactivity and toxicity/pharmacokinetics; Discussing Phase 1 clinical data of BB-1701; Exploring the future of Bliss Bio's BB-1701 Phase classification: P2 --> P1 | N=131 --> 25
- | Halaven (eribulin mesylate) / Eisai
Journal: Radiation recall dermatitis induced by eribulin mesylate. (Pubmed Central) - Aug 7, 2023
Phase classification: P2 --> P1 | N=131 --> 25 No abstract available
- | Ibrance (palbociclib) / Pfizer, Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker: A Case of Breast Carcinoma That Changed Subtype to Squamous Cell Carcinoma after Chemotherapy (Pubmed Central) - Jul 31, 2023
left breast cancer T2N2bM1(HEP)(ER 90%, PR 70%, HER2 2+, FISH-)at another hospital and participated in the PATHWAY study(tamoxifen plus goserelin plus palbociclib/placebo)...She was treated at our hospital thereafter, with capecitabine plus cyclophosphamide, palbociclib plus fulvestrant plus leuprorelin, paclitaxel plus bevacizumab, eribulin, EC therapy, and docetaxel...Therefore, left mastectomy plus pectoralis major muscle resection was performed. The patient died one month after the operation.
- Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of eribulin plus anlotinib and camrelizumab in advanced or metastatic retroperitoneal liposarcoma (RLPS) or leiomyosarcoma (RLMS): A single-center retrospective cohort study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3388;
Due to AEs, 15 pts (25.0%) discontinued treatment and 6 (16.7%) reduced their eribulin dose. Conclusions Eribulin plus anlotinib and camrelizumab demonstrated clinically meaningful efficacy and a manageable safety profile in pts with advanced or metastatic RLPS or RLMS, especially in those with RLMS.
- Halaven (eribulin mesylate) / Eisai, farletuzumab ecteribulin (MORAb-202) / Eisai, BMS
Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2348;
Intratumoral imaging analysis using tumors on day 21st showed an association between the antitumor effect and intratumoral accumulation of eribulin. Conclusions These results suggest that FZEC may be a promising treatment for FR?-expressing EC of all four molecular subtypes.
- Halaven (eribulin mesylate) / Eisai
Health outcomes of treatment sequences with eribulin or other single agents' chemotherapy for treating relapsed metastatic HER2-negative breast cancer () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2069;
The results were consistent across the sensitivity analyses conducted. Table: 462P Conclusions Starting single agent ChT with ERI vs. CAP or TPC is associated with improved health outcomes for 2L-4L HER2- MBC management.
- Ibrance (palbociclib) / Pfizer
Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC): A prospective, real-world study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2062;
Conclusions In this real life experience, treatments beyond ET plus P failure provided limited but comparable clinical benefit. The physician's choice was clearly driven by visceral burden of disease; the inflammatory status seems to have a detrimental effect on PFS2.
- Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial (Bilbao Auditorium - NCC) - Jul 27, 2023 - Abstract #ESMO2023ESMO_799;
P3
PC could be either trastuzumab combined with capecitabine or vinorelbine or eribulin or lapatinib plus capecitabine...The final OS results confirm a trend towards a numerically prolonged OS (statistically non-significant) in the T-Duo group compared with PC group. Safety was aligned with the primary analysis, with no new signals identified.
- | Halaven (eribulin mesylate) / Eisai
New trial, Metastases: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01). (clinicaltrials.gov) - Jul 20, 2023
P=N/A, N=120, Active, not recruiting, Sponsor: Fujian Cancer Hospital
- | everolimus / Generic mfg.
New P3 trial, Metastases: BCTOP-T-M03: Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype (clinicaltrials.gov) - Jul 20, 2023
P3, N=203, Not yet recruiting, Sponsor: Fudan University
- |||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open, Metastases: SHR-A1811-III-306: SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial (clinicaltrials.gov) - Jul 20, 2023
P3, N=530, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Safety was aligned with the primary analysis, with no new signals identified. Not yet recruiting --> Recruiting
- || Halaven (eribulin mesylate) / Eisai, eribulin liposomal (E7389-LF) / Eisai, Opdivo (nivolumab) / Ono Pharma, BMS
P1/2 data, Clinical Trial,Phase I, Journal, PD(L)-1 Biomarker, Metastases: Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib. (Pubmed Central) - Jul 16, 2023
The combination was tolerable overall; 4 patients had a partial response. Vasculature and immune-related biomarker levels increased, suggesting vascular remodeling.